Arvinas Inc.
11/19/2024 | Press release | Distributed by Public on 11/19/2024 05:00
Material Event Form 8 K
Item 8.01 Other Events.
Arvinas, Inc. (the "Company"), along with Pfizer, Inc., regularly evaluate enrollment and blinded event rates in the ongoing VERITAC-2 Phase 3 second-line clinical trial of vepdegestrant as a monotherapy in patients with metastatic breast cancer. Based on current trial status, which completed enrollment in the fourth quarter of 2024, the primary completion date for this clinical trial has been reprojected from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.